Parosteal osteosarcomas are rare low-grade bony malignancies with a slight female preference found in the second to fourth decades of life [1]. Okuda et al. reported a female to male ratio of 1.28:1 in their report of 228 patients [1]. Parosteal osteosarcomas arise from the periosteum of metaphyseal long bones, most commonly in the distal femur, proximal tibia, and proximal humerus [1, 2]. However, there have been reports of parosteal osteosarcomas arising from various locations, such as the distal radius, talus, cranium, mandible, ribs, clavicle, and tarsal bones [3, 4, 8].
Although they were once thought to be a subtype of intramedullary osteosarcomas, the World Health Organization (WHO) now recognizes parosteal sarcomas as a distinct entity with its own unique clinical course and pathologic characteristics [5]. On presentation, patients most commonly complain of a painless growing mass and range of motion limitations in cases in which the tumor arises adjacent to a joint [6]. Radiographically, the tumor appears as a cortically based exophytic ossified mass without extension into the medullary canal [7]. They can often be mistaken for osteochondromas, which also appear as cortically based bony masses, but present with continuity of the medullary space between the mass and the native bone.
Histological and immunochemical analysis showed a fibro-osseous lesion with hypocellular spindle cell stroma containing trabeculae of bone. Spindle cells usually have minimal cytologic atypia and limited mitotic activity [1]. Okuda et al delineated guidelines for identifying parosteal osteosarcomas that involve radiographic evidence of bony origin and histology showing well-formed osteoid, spindle-cell stroma and overall well-differentiated low-grade appearance. They also noted that in cases with medullary involvement, there must be less than 25% involvement of the cavity [1]. Molecular studies can aid in the diagnosis of this malignancy over its benign imitators. Yoshida et al examined MDM2 and CDK4 gene amplifications to differentiate parosteal osteosarcoma from osteochondroma. The authors found that all of the parosteal osteosarcoma samples demonstrated positivity to CDK4 gene amplification, and the majority showed positivity to MDM2 gene amplification [9]. Duhmel et al reported that MDM2 could be utilized to distinguish parosteal osteosarcoma from conventional osteosarcoma, as 85% of parosteal osteosarcomas in their sample were MDM2 amplification positive [10].
Parosteal osteosarcomas are well-differentiated malignant tumors with low local recurrence rate and metastatic potential. Treatment consists of wide resection without chemotherapeutic intervention. Ruengwanichayakun et al demonstrated that the degree of dedifferentiation of these tumors had the largest inverse effect on long-term survival. They reported 96% 5-year survival in parosteal osteosarcomas compared to 65% in cases with dedifferentiation. Similarly, they reported the 10-year survival rates of the two groups to be 96% and 60%, respectively [11].
In this case, there was a significant delay in treatment due to various social factors. The patient initially presented with advanced local disease and was lost to follow-up for an additional year. Surgical resection was further delayed following diagnosis due to the patient's desire to participate in his high school sports season. Fortunately, despite the delayed presentation, the patient’s lesion did not worsen significantly on repeat plain radiographs. This reflects the slowly evolving natural history of this tumor.
Direct local invasion of adjacent bone has been reported in aggressive bony malignancies and has been associated with a higher likelihood of local recurrence and poorer outcomes [12]. In our case, both preoperative imaging and intraoperative histology demonstrated tumor invasion causing erosion of the adjacent ulna. This phenomenon has not been characterized previously in parosteal osteosarcomas of the distal radius in skeletally immature patients. This may be due to the fact that these lesions more commonly arise in the distal femur, proximal tibia, or humerus, where direct bony abutment to an adjacent bone is far less likely. The delay in presentation also played a role in allowing the tumor to grow to a sufficient size to allow for adjacent bony invasion. It may be that in previously reported cases, the tumor was resected prior to reaching a size to abut and efface an adjacent bone. We feel that this is likely a phenomenon only seen in later stages of the disease. Although this demonstrates the slow-growing nature of parosteal osteosarcomas, we recommend expedited treatment, as local bony invasion may require more aggressive resection and complex reconstruction endeavors.
Utilizing the mean distal ulnar growth rate and negative ulnar variance measurements, we were able to estimate when the tumor began impeding the distal ulnar growth and approximate how long the tumor had been growing. We utilized the Hafner method to calculate the ulnar variance for our patient. In short, this is a validated method of measuring negative ulnar variance in pediatric patients by measuring the difference between the most proximal point to the radial and ulnar metaphysis (PRPR) and the difference between the most distal point of the radial and ulnar metaphysis (DIDI). Even at initial presentation, our patient had approximately 1.35 to 1.6 cm of ulnar shortening. We assumed the mean growth rate of the distal ulna to be approximately 0.9 cm per year; the mean ulnar growth rate in skeletally immature males is reportedly 1.1 cm per year, with the distal ulna accounting for 85% of the growth [13]. Using these values, we estimated that the tumor had been impeding the growth of the ulna for approximately 1.5 to 1.9 years even prior to initial presentation. Of note, this only accounts for when the tumor was of sufficient size to start impeding the growth of the distal ulna. Although an estimate, this does give insight into the age of our patient’s tumor and how slow growing it is.
Finally, our case also demonstrated the common diagnostic difficulties associated with this malignancy. Pathology can often have a benign appearance, making molecular studies crucial in making the correct diagnosis. Aberrant gene signaling can only be detected at the active margins of the tumor, and as in our case, these can be prone to sampling errors. Adhering to careful biopsy techniques and sampling multiple areas of the tumor, making sure to include active borders of bony growth are paramount. Furthermore, communication with the pathology team regarding the differential diagnosis, clinical presentation, and molecular studies needed can shorten the time to diagnosis and treatment.